Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
T Rowe Price
AddedMar 19, 2024
UpdatedJul 16, 2026
T Rowe Price

T Rowe Price

Operating

Global investment firm managing $1.6T+ assets. Serving clients in 47 countries.

Location
Baltimore, MD, US
Founded
2000
Firm
Compare
Portfolio
Fundraising
Employees
News
Website

Investments

SambaNova Systems
SambaNova Systems
Series F

Total Raised

$2.5B

Rounds

8

Series F$1BJuly 2026
Airwallex
Airwallex
Series H

Total Raised

$1.9B

Rounds

15

Series H$320MJune 2026
Series G$330MDecember 2025
Bending Spoons
Bending Spoons

Total Raised

$4.2B

Rounds

7

Series E$270MOctober 2025
iCapital Network
iCapital Network

Total Raised

$1.5B

Rounds

13

Series F$820MJuly 2025
Stash
Stash
Series H

Total Raised

$146M

Rounds

2

Series H$146MMay 2025
KoBold Metals
KoBold Metals
Series C

Total Raised

$944.5M

Rounds

4

Series C$537MJanuary 2025
Series B$195MJune 2023
Honor
Honor
Series E

Total Raised

$695M

Rounds

7

Series E$70MJune 2024
Odyssey Therapeutics
Odyssey Therapeutics

Total Raised

$487M

Rounds

3

Series C$101MDecember 2023
RefleXion Medical
RefleXion Medical

Total Raised

$675.1M

Rounds

11

Series Unknown$105MNovember 2023
Apiture
Apiture

Total Raised

$69M

Rounds

4

Series Unknown$10MNovember 2023
Stash
Stash

Total Raised

$520M

Rounds

12

Convertible Note$40MOctober 2023
Generate Biomedicines
Generate Biomedicines

Total Raised

$693M

Rounds

3

Series C$273MSeptember 2023
Databricks
Databricks

Total Raised

$29.2B

Rounds

14

Series I$684.6MSeptember 2023
Sortera Alloys.
Sortera Alloys.

Total Raised

$52.5M

Rounds

4

Series C$30.5MAugust 2023
Redwood Materials
Redwood Materials

Total Raised

$3.8B

Rounds

8

Series D$1BAugust 2023
Rapport Therapeutics
Rapport Therapeutics

Total Raised

$250M

Rounds

2

Series B$150MAugust 2023
Genesis Therapeutics
Genesis Therapeutics

Total Raised

$256.1M

Rounds

5

Series B$200MAugust 2023
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Ring Therapeutics
Ring Therapeutics

Total Raised

$253.5M

Rounds

3

Series C$86.5MMarch 2023
VerAI Discoveries
VerAI Discoveries

Total Raised

$15.4M

Rounds

2

Series A$12MMarch 2023
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023
SandboxAQ
SandboxAQ
Series E

Total Raised

$950M

Rounds

5

Series Unknown$500MFebruary 2023
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series D$178MNovember 2022